Three groups were classified at the baseline into an aPL+ group with 81 aPL-positive patients without clinical thrombosis; an aPL- group with 107 aPL negative patients; and a secondary antiphospholipid syndrome (APS) group with 84 aPL+ patients who met the Sapporo criteria. The gene discussed is FASLG; the disease is Venous thrombosis.